



Method for Scaled-Up Production of Recombinant rAAV Vectors

The University of Florida is currently seeking companies interested in commercializing a novel method for scaling-up production of recombinant adeno-associated viral (rAAV) vectors. Scaleable production of rAAV vectors remains a major obstacle to the clinical application of AAV gene therapy vectors. Further, yields of virions produced by current methods are typically low, and supplies are limited and expensive. University of Florida researchers have developed a novel Baculovirus-based system of rAAV production designed to significantly increase production efficiencies and address the limitations that have prevented the development of viable large-scale production of rAAV.

Applications

Large-scale production of rAAV vectors for clinical or research applications

Advantages

- ◆ Enables large-scale production of rAAV vectors, increasing availability to meet demand
- ◆ Technology provides a relatively simple and cost effective method for AAV production, making it ideal for large scale, bio-reactor size, commercial production by reducing production costs
- ◆ Promotes further research and new gene therapy protocols due to increased efficiency and greater availability of AAV vector

The Technology

This technology utilizes two novel baculovirus vectors in its rAAV production system. Unlike previously described baculovirus-based rAAV production systems these vectors are stable during propagation using serial passaging. This novel characteristic supports large-scale replication of rAAV vectors, allowing large-scale production of rAAV vectors for a variety of clinical and research applications.

contact

Elizabeth Garami
University of Florida
Office of Technology Licensing
352/392-8929 • email: egarami@ufl.edu
Reference UF #11372 ~ Patent pending



UNIVERSITY OF
FLORIDA

Office of Technology Licensing

*Facilitating Technology Transfer
To Serve Faculty and Community*
www.otl.ufl.edu